Enzalutamide (enzalutamide) indication scope and introduction to the main diseases treated

Enzalutamide, also known as enzalutamide, is a new type of androgen receptor inhibitor mainly used to treat prostate cancer. It inhibits the signaling pathway of androgen receptors, thereby blocking the stimulating effect of androgens on tumor cells, slowing or inhibiting the development of prostate cancer. At present, enzalutamide has been widely used in the treatment of various stages of prostate cancer and is one of the important treatments for patients with advanced prostate cancer.

One of its main indications is metastatic castration-resistant prostate cancer (mCRPC). This is when the tumor has progressed despite treatment with castration (surgery or medication to lower testosterone) and has spread to distant sites. At this stage, enzalutamide can prolong patient survival, slow down tumor progression, and improve quality of life. It is suitable for patients who have not received chemotherapy before or have received docetaxel chemotherapy.

In addition, enzalutamide is also approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC), that is, patients who have not developed distant metastasis but have failed to respond to traditional castration therapy. The use of enzalutamide at this stage can significantly extend the time for metastasis to occur (MFS), delay disease progression, and help patients achieve longer symptom-free survival.

In recent years, enzalutamide has also expanded to the treatment of **metastatic hormone-sensitive prostate cancer (mHSPC) ** , that is, the stage where the disease is still sensitive to androgen suppression but has metastasized. The use of enzalutamide in combination with traditional ADT (androgen deprivation therapy) at this stage can further prolong the overall survival of patients and has become an important part of the current multi-line treatment strategy. Overall, enzalutamide has covered multiple stages of prostate cancer from hormone-sensitive to castration-resistant, from non-metastatic to widely metastatic.

Reference materials:https://www.drugs.com/